IDO1 and head and neck squamous cell carcinoma: It is worth mentioning that three of these immune markers belong to the main immune checkpoint pathways in HNSCC, namely PD-1, CTLA-4, and LAG3, which suggests that combination treatment with IDO1 inhibitors may be beneficial for some patients.